REG - Yooma Wellness Inc. - Yooma Wellness Q2-2021 results

Yooma WellnessAnnouncement

31/08/2021 07:05

RNS Number : 1108K
  
Yooma Wellness Inc.
  
31 August 2021
  
 

31 August 2021
 
Yooma Wellness Inc.
("Yooma" or the "Company" or the "Group")
 
 
Yooma Wellness Reports Results for Second Quarter of 2021
 
Second quarter lays the foundation for Yooma's strategy to become a leading global CBD and wellness platform
Toronto, Ontario, Canada, August 31, 2021 - Yooma Wellness Inc. ("Yooma" or the "Company") (CSE: YOOM, AQSE:YOOM), a Toronto-based vertically-integrated global wellness platform that develops and markets a portfolio of wellness brands, today released its interim financial statements (the "Financial Statements") for the three-month period ended June 30, 2021 (the "Reporting Period").  A summary of Yooma's operational and financial highlights during the Reporting Period are set out below and more detailed information is contained in the Financial Statements and related management discussion and analysis which are available on Yooma's SEDAR page at www.sedar.com.
 
"Yooma has made significant progress since completing its public listing earlier this year, including a number of exciting acquisitions in the CBD and wellness space and a successful capital raise of up to US$17.1 million," said Yooma Chairman, Lorne Abony, "Our efforts during the second quarter laid the foundation for the buy-and-build strategy that we recently outlined to investors at the time of our UK financing and dual-listing - to buy and build companies globally, focused on increasing the Company's top-line revenue, leveraging our integrated supply chain and expanding distribution for our existing portfolio."
Operational Highlights (Q2 2021)
Yooma is in the early stages of implementing its plan to become a vertically-integrated global leader in the marketing, distribution and sale of wellness products, including hemp seed oil and hemp-derived cannabinoid ("CBD") ingredients.  Significant operational highlights and activities during the Reporting Period included: 
-      Integration:  Integrating significant acquisitions from the first quarter of 2021 into Yooma's global platform, including (i) Socati Corp., a U.S.-based manufacturer and seller of premium-quality CBD ingredients and consumer products, and (ii) UK and European wellness brands MYO Plant Nutrition, Blossom, What the Hemp and Hello Joya. 
 
-      Dual-Listing:  Laying the groundwork for the dual-listing of the Company's common shares on the Aquis Stock Exchange Growth Market ("AQSE"), a UK-based multilateral trading facility for entrepreneurial companies seeking visibility and access to growth capital in Europe.  The dual-listing was successfully completed and the Company's common shares began trading on the AQSE after the end of the Reporting Period, on August 10, 2021. 
 
-      Capital Raising: Conducting capital raising efforts in North America and the UK in connection with an equity financing to be completed concurrently with the dual-listing of the Company's common shares on the AQSE.  The equity financing was successfully completed after the end of the Reporting Period, on August 10, 2021, raising proceeds of US$10.3 million with the potential to raise an additional US$6.8 million if an option granted to a strategic investor is exercised on or before September 17, 2021. 
 
-      Transaction Opportunities:  Identifying and working with targets for potential acquisitions and future commercial partnerships as part of Yooma's buy-and-build strategy to become a global CBD and wellness platform.  During the Reporting Period the Company entered into non-binding letters of intent for several potential acquisitions. The first of these acquisitions was completed after the Reporting Period on August 19, 2021, when Yooma acquired UK market-leader Vitality CBD Ltd., a market-leading distributer of CBD products including oils and sprays in a wide range of flavours and strengths, edibles, and a specially developed and formulated range of CBD skin care cosmetic products. 
 
-      Shift in Market Focus:  Shifting the Company's focus away from China and onto other markets where it has been experiencing significant growth, following an announcement during the Reporting Period that China's National Medical Products Administration added CBD to its "List of Prohibited Use Cosmetic Ingredients".  The announcement resulted in a number of online marketplaces, including those which Yooma had been working with, to restrict promotion and marketing efforts for CBD products, eliminating much of the progress Yooma had made in China to date. 
Selected Financial Highlights (Q2 2021)
During the Reporting Period, the Company generated revenues of US$2,177,337, but experienced net and comprehensive losses of US$3,193,674, reflecting significant cost of sales (US$1,934,628) and expenses (US$3,311,947) relating primarily to the integration of previously acquired businesses into Yooma's global platform, expenses incurred in connection with capital raising activities and the AQSE dual-listing, and the expansion of the Yooma team to meet the demands of its growing business.  Key financial highlights during the Reporting Period included the following:
 



All amounts in US dollars:


For the three month period ended 


For the three month period ended 


For the six month period ended 


For the six month period ended 




June 30,


June 30,


June 30,


June 30,




2021


2020


2021


2020


































































































Revenue






$      2,177,337 






 $       -   






 $        2,781,017 






$        -   




Cost of sales






      (1,934,628)






       
 -   






       (2,208,155)






       -                               




Gross profit










      242,708          






      
-


                                 


       572,862






 -




 
Expenses




































Depreciation and amortization










$ 212,669 






$     -






$231,523 






$      -




Consulting fees                        






227,566






132,808






           390,689






151,840




Professional fees






511,931






83,745






           901,727






108,415




Listing expense










     -   






  -   










           960,725








Stock-Based compensation










52,304






  -   










             99,602




Office and administrative






2,307,477 






  232,089






3,485,700






233,380
















3,311,947






    448,642










6,069,967






 










































Net loss before other income and expenses


      $      (3,069,239)






 $ (448,642)






    $    (5,497,105)






$ (493,635)




 
Assets write-off 










 (134,810)






   -






(134,810)
















Other income










    10,374 






    17,499 


 
 


62,848 






17,499 










































Net loss and comprehensive loss for the period                                 






                            $(3,193,674)






                               $  (431,143)






                            $(5,569,066)






                          $(476,136)




Loss per share - basic and diluted:       






$       (0.04)






 $    (0.03)






      $    (0.12)






$   (0.02)










































Weighted average number of common shares outstanding - basic and diluted:






75,540,765






16,349,517






46,977,197






19,735,819


















 
 
About Yooma Wellness Inc.
Yooma's mission is to build a vertically-integrated global leader in the manufacturing, marketing, distribution, and sale of wellness products including hemp seed oil and hemp-derived and cannabinoid (CBD) ingredients. The company leverages strategically curated sales channels and ecommerce networks to deliver a diverse mix of wellness products through operating subsidiaries in the United States, United Kingdom, France and Japan. Learn more at www.yooma.ca.
The directors of the Company accept responsibility for the contents of this announcement.



 
For further information, please contact:












Yooma Wellness Inc.
Jordan Greenberg, CEO
jgreenberg@yooma.ca
 






Via Buchanan
Tel:+44 (0) 20 7466 5000
 




AQSE Corporate Adviser:
Peterhouse Capital Limited
Guy Miller / Mark Anwyl
 






Tel: +44 (0) 20 7469 0930
Tel: +44 (0) 7990 139 093




Media Enquiries (Canada):
Michael Bancroft
michaelbancroft@globalive.com
 












Media Enquiries (UK / Europe):
Buchanan
Henry Harrison-Topham / Jamie Hooper
Ariadna Peretz / George Beale
yooma@buchanan.uk.com
 






Tel: +44 (0) 20 7466 5000
www.buchanan.uk.com



 
Notice regarding Forward Looking Statements
All information included in this press release, including any information as to future financial or operating performance and other statements of Yooma that express management's expectations or estimates of future performance or activities, other than statements of historical fact, constitute forward-looking information or forward-looking statements (collectively, "forward-looking statements") within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management's current expectations and plans relating to the future. Wherever possible, words such as "will", "intend", "believe", "future", "go forward", "to become", "pursuit", "pursuing", "potential", "plan" or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, economic conditions and anticipated courses of action, including statements about Yooma's mission and strategic plan; any potential acquisitions under non-binding letters of intent; and the nature and focus of its business going forward.
There are many risks and uncertainties that may affect forward-looking statements including, among others, regulatory risk in each jurisdiction in which Yooma does or intends to operate; the uncertainties, effects of and responses to the COVID-19 pandemic; reliance on licenses; competition; dependence on senior management and key personnel; general business risk and liability; regulation of the CBD industry; changes in laws, regulations and guidelines; compliance with laws; limited operating history; unfavourable publicity or consumer perception; product liability, risks related to intellectual property; product recalls; difficulties with forecasts; management of growth; litigation; the possibility that the Company's strategic investor will not exercise its option to participate in the Company's equity financing, or will be unable to satisfy the conditions to close that financing; potential for a breakdown in the relationship between Yooma and its potential strategic acquisition targets, or the inability to satisfy the conditions necessary to complete such acquisitions or to complete them on the terms described herein; and other matters which are beyond the control of Yooma. Although the forward-looking statements contained herein reflect management's current beliefs and reasonable assumptions based upon information available to management as of the date hereof, Yooma cannot be certain that actual results will be consistent with such forward-looking information. Yooma cautions you not to place undue reliance upon any such forward-looking statements. Yooma disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of Yooma.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NEXPMMLTMTAJBRB